Abstracts Archive - Page 1846 of 2607 - ACR Meeting Abstracts

Abstract Number: 2884 • 2015 ACR/ARHP Annual Meeting
Epidemiological Parameters Affecting Therapeutic Response in Psoriatic Arthritis Patients
Michail P. Migkos¹, George Somarakis², Evripidis Kaltsonoudis³, Theodora E. Markatseli⁴, Paraskevi V. Voulgari^5,6 and Alexandros A. Drosos⁷, ¹Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Fellow in Rheumatology, Ioannina, Greece, ²Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, University of Ioannina, Rheumatology Clinic, Ioannina, Greece, ³Rheumatology Clinic, Department of Internal Medicine, Rheumatologist, Ioannina, Greece, ⁴Rheumatology Clinic, Department of Internal Medicine, Fellow in Rheumatology, Ioannina, Greece, ⁵Rheumatology Clinic, Department of Internal Medicine, Assistant Professor of Rheumatology, Ioannina, Greece, ⁶Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Assistant Professor of Rheumatology, Ioannina, Greece, ⁷Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Professor of Medicine/Rheumatology, Ioannina, Greece
Background/Purpose: Published data have shown that epidemiological parameters such as Body Mass Index (BMI), gender and disease duration may affect the therapeutic response in psoriatic…
Abstract Number: 2885 • 2015 ACR/ARHP Annual Meeting
Long-Term Effects of Etanercept on Patient-Reported Outcomes in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Results of a Phase III Study
Filip van Den Bosch^1,2, Edit Drescher³, Jan Rosa⁴, Ronald Pedersen⁵, Randi Bonin⁶, Bonnie Vlahos⁷, Jack F Bukowski⁶ and Sameer Kotak⁸, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Csolnoky Ferenc Hospital, Veszprém, Hungary, ⁴Mediscan Group, Prague, Czech Republic, ⁵Department of Biostatistics, Pfizer, Collegeville, PA, ⁶Clinical Affairs, Pfizer, Collegeville, PA, ⁷GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ⁸Global Health and Value, Pfizer, New York, NY
Background/Purpose: In patients with active, NSAID-resistant, non-radiographic axial spondyloarthritis (nr-axSpA) who participated in the multiphase, randomized, placebo (PBO)-controlled EMBARK study (ClinicalTrials.gov identifier: NCT01258738), health-related quality-of-life…
Abstract Number: 2886 • 2015 ACR/ARHP Annual Meeting
Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis and Psoriasis: Results from a Pooled Safety Analysis
Philip J. Mease¹, Iain B. McInnes², Alice B. Gottlieb³, Albert Widmer⁴, Luminita Pricop⁵ and Shephard Mpofu⁴, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Immunology, Infection and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Dermatology, Tufts Medical Center, Boston, MA, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been shown to improve the signs and symptoms of psoriasis and psoriatic arthritis (PsA).1–3 Here, we…
Abstract Number: 2887 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials
Atul A. Deodhar¹, Dominique Baeten², Joachim Sieper³, Brian Porter⁴, Albert Widmer⁵ and Hanno Richards⁵, ¹Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³University Clinic Benjamin Franklin, Berlin, Germany, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in 2 Phase 3, randomized, double-blind, placebo (PBO)-controlled studies, MEASURE…
Abstract Number: 2888 • 2015 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials
Dafna D. Gladman¹, Arthur Kavanaugh², Adewale O. Adebajo³, Juan J. Gomez-Reino⁴, Jürgen Wollenhaupt⁵, Maurizio Cutolo⁶, Georg A. Schett⁷, Eric Lespessailles⁸, Melissa McIlraith⁹, ChiaChi Hu⁹, Christopher J. Edwards¹⁰, Charles A. Birbara¹¹ and Philip J. Mease¹², ¹Toronto Western Hospital, Toronto, ON, Canada, ²University of California, San Diego School of Medicine, LaJolla, CA, ³University of Sheffield, Sheffield, United Kingdom, ⁴Hospital Clinico Universitario, Santiago, Spain, ⁵Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁶University of Genova, Genova, Italy, ⁷University of Erlangen-Nuremberg, Erlangen, Germany, ⁸University of Orléans, Orléans, France, ⁹Celgene Corporation, Warren, NJ, ¹⁰University Hospital Southampton, Southampton, United Kingdom, ¹¹University of Massachusetts Medical School, Worcester, MA, ¹²Rheumatology Research, Swedish Medical Center, Seattle, WA
Background/Purpose: Apremilast (APR), a PDE4 inhibitor, helps regulate immune responses in psoriatic arthritis (PsA). PALACE 1, 2, and 3 compared apremilast (APR) efficacy/safety with placebo…
Abstract Number: 2889 • 2015 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Improvements in Nail and Scalp Psoriasis and Psoriasis Area and Severity Index in Patients with Moderate to Severe Plaque Psoriasis
Kim Papp¹, Jeffrey Crowley², Carle Paul³, Melinda Gooderham⁴, Kristian Reich⁵, ChiaChi Hu⁶, Robert M. Day⁶ and Christopher E.M Griffiths⁷, ¹Probity Medical Research, Waterloo, ON, Canada, ²Bakersfield Dermatology, Bakersfield, CA, ³Toulouse University, Hôpital Larrey, Toulouse, France, ⁴SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada, ⁵SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany, ⁶Celgene Corporation, Warren, NJ, ⁷Dermatology Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose: Scalp and nail psoriasis are difficult-to-manage manifestations of psoriasis and psoriatic arthritis (PsA). Nail involvement occurs in ~80% of pts with PsA and can…
Abstract Number: 2890 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis in Anti-TNF-Naïve Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials
Dominique Baeten¹, Ricardo Blanco², Piet Geusens³, Joachim Sieper⁴, Tseng Jui-Cheng⁵, Ruvie Martin⁶, Brian Porter⁶ and Hanno Richards⁷, ¹Academic Medical Center/ University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Maastricht University, Maastricht, Netherlands, ⁴University Clinic Benjamin Franklin, Berlin, Germany, ⁵Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Anti‒TNFs are the only biologics currently approved for ankylosing spondylitis (AS). There is a significant unmet need in those patients (pts) with an inadequate…
Abstract Number: 2891 • 2015 ACR/ARHP Annual Meeting
Assessment of Disability Levels in a Cohort of 1,489 Patients with Active Psoriatic Arthritis, and the Effect of Apremilast Treatment: Pooled Data from Three Phase III, Randomized, Controlled Trials
Philip J. Mease¹, Jürgen Wollenhaupt², Stephen Hall³, Filip van Den Bosch⁴, Eric Lespessailles⁵, Melissa McIlraith⁶, Lichen Teng⁶ and Christopher J. Edwards⁷, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Schön Klinik Hamburg Eilbek, Hamburg, Germany, ³Monash University, CabriniHealth, Melbourne, Australia, ⁴Rheumatology, Ghent University Hospital, VIB, Ghent, Belgium, ⁵University of Orléans, Orléans, France, ⁶Celgene Corporation, Warren, NJ, ⁷University Hospital Southampton, Southampton, United Kingdom
Background/Purpose: PsA, a chronic systemic inflammatory disease, reduces physical function and QOL. Treatment improves/maintains functionality. PALACE 1-3 compared apremilast (APR) efficacy/safety with placebo (PBO) in…
Abstract Number: 2892 • 2015 ACR/ARHP Annual Meeting
Statin Treatment in Patients with Ankylosing Spondylitis
Grunde Wibetoe¹, Eirik Ikdahl¹, Tore K. Kvien², Silvia Rollefstad¹ and Anne Grete Semb³, ¹Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD). In the general population, CVD risk reduction can be achieved by lipid…
Abstract Number: 2893 • 2015 ACR/ARHP Annual Meeting
Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis after 16 Weeks of Golimumab Treatment
Walter Maksymowych¹, Sean P. Curtis², Maxime Dougados³, Gina Bergman², Susan Huyck², Anjela Tzontcheva² and Joachim Sieper⁴, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Merck & Co., Inc., Kenilworth, NJ, ³Paris-Descartes University, Paris, France, ⁴University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: Chronic inflammation, back pain, and progressive spinal stiffness associated with axial spondyloarthritis (axSpA) can decrease quality of life (QoL). The purpose of this study…
Abstract Number: 2894 • 2015 ACR/ARHP Annual Meeting
The Majority of Patients with Moderate to Severe Psoriatic Arthritis Had Existing Structural Damage, Predisposing Them to Further Progression, Which Was Markedly Inhibited By Adalimumab
Pranav Sheth¹, Philip J. Mease², Yihan Li³, Fabiana Ganz⁴ and Maja Hojnik⁵, ¹Group Health Associates, Trihealth, Cincinnati, OH, ²Seattle Rheumatology Associates, Seattle, WA, ³AbbVie Inc., North Chicago, IL, ⁴Neuhofstrasse 23, AbbVie AG, Baar, Switzerland, ⁵AbbVie, Ljubljana, Slovenia
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) may experience structural damage if not appropriately treated. The purpose was to determine 1) the frequency of radiographic…
Abstract Number: 2895 • 2015 ACR/ARHP Annual Meeting
Intraarticular Sacroiliac Corticosteroid Injections in Ankylosing Spondylitis
Seunghun Lee¹, Sung Won Lee², Yoonah Song¹, Il-Hoon Sung³ and Tae-Hwan Kim², ¹Department of Radiology, Hanyang University College of Medicine, Seoul Hospital, Seoul, South Korea, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Department of Orthopaedic Surgery, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease which involves axial skeleton. NSAIDs are drug of choice and biologic disease-modifying anti-rheumatic drugs (DMARDs) are strongly…
Abstract Number: 2896 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Efficacy and Safety Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Dominique Baeten¹, Jurgen Braun², Joachim Sieper³, Maxime Dougados⁴, Atul A. Deodhar⁵, Xenofon Baraliakos⁶, Brian Porter⁷, Yankun Gong⁸ and Hanno Richards⁹, ¹1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, Herne, Germany, ³University Clinic Benjamin Franklin, Berlin, Germany, ⁴Paris-Descartes University, Paris, France, ⁵Oregon Health and Sciences University, Portland, OR, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Beijing Novartis Pharma Co. Ltd., Beijing, China, ⁹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) over 52 weeks (wks) in the randomized, double-blind, placebo (PBO)-controlled,…
Abstract Number: 2897 • 2015 ACR/ARHP Annual Meeting
Predictors of Organ Damage Progression and Impact on Health-Related Quality of Life in Systemic Lupus Erythematosus
Alexandra Legge¹, Steve Doucette² and John G. Hanly³, ¹Department of Medicine, Dalhousie University, Halifax, NS, Canada, ²Dalhousie University and Capital Health, Halifax, NS, Canada, ³Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada
Background/Purpose: To describe cumulative organ damage in a longitudinal cohort of SLE patients and to evaluate the impact of key disease-related factors, medical therapies, demographic…
Abstract Number: 2898 • 2015 ACR/ARHP Annual Meeting
Erythrocytes, Acanthocytes, and Proteins in Urine Reflect Lupus Nephritis Histology
Marco Ulises Martinez-Martinez¹, Lilia Llamazares-Azuara², David Martínez-Galla³, Francisco Valadez-Castillo⁴, Peter Mandeville⁴, Jaime Antonio Borjas García⁵ and Carlos Abud-Mendoza¹, ¹Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ²Laboratorio Renal, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ³Patología, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁴Faculty of Medicine, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁵Regional Unit of Rheumatology and Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico
Background/Purpose: Hematuria in lupus nephritis (LN) is secondary to the passage of red blood cells (RBCs) through glomerular abnormalities. Dysmorphic RBCs are associated with glomerulonephritis,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].